Val­ne­va’s sec­ond-gen Covid vac­cine plans up in the air as it looks for part­ner

Val­ne­va has had a rocky cou­ple of months.

While Eu­ro­pean au­thor­i­ties rec­om­mend­ed its non-mR­NA Covid shot for pri­ma­ry vac­ci­na­tion in adults in late June, the Eu­ro­pean Com­mis­sion an­nounced a month lat­er that it was cut­ting its pur­chase of the vac­cine from 60 mil­lion to 1.25 mil­lion dos­es.

As it at­tempts to breathe life back in­to its Covid vac­cine pro­gram, Val­ne­va an­nounced Mon­day morn­ing that it was look­ing for a part­ner to fund its de­vel­op­ment of a sec­ond-gen vac­cine. It said it is cur­rent­ly in dis­cus­sions with a prospec­tive part­ner, but not­ed that dis­cus­sions could go on for sev­er­al months and may not lead to any­thing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER